Biomarkers of Extracellular Matrix Turnover

Heart Failure Clinics

Volumn 5, Issue 4, 2009, Pages 589-599

  Zannad, Faiez ^a,b,c   Pitt, Bertram ^d  

^a Ctr Hospitalier Univ de Nancy   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biomarkers; Collagen; Extracellular matrix; Fibrosis; Heart failure; Metalloproteinases

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; EPLERENONE; ETANERCEPT; GELATINASE A; GELATINASE B; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 18 BINDING PROTEIN; INTERSTITIAL COLLAGENASE; IRBESARTAN; LOSARTAN; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROPONIN; TYPE I PYRIDINOLINE CROSS LINKED CARBOXY TERMINAL TELOPEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE SEVERITY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; SCINTIANGIOGRAPHY;

ALDOSTERONE ANTAGONISTS; BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA;

EID: 67650601382     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.04.010     Document Type: Review

References (70)

1. Bishop J.E., and Laurent G.J. Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J 16 (1995) 38-44
2. Zannad F., Dousset B., and Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 38 (2001) 1227-1232
3. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 12 (2002) 97-101
4. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
5. Laviades C., Varo N., Fernandez J., et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98 (1998) 535-540
6. Weber K.T. Monitoring tissue repair and fibrosis from a distance. Circulation 96 (1997) 2488-2492
7. Lopez B., Gonzalez A., Querejeta R., et al. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 23 (2005) 1445-1451
8. Risteli J., and Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological, and methodological aspects. J Hepatol 22 (1995) 77-81
9. Jensen L.T., Horslev-Petersen K., Toft P., et al. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation 81 (1990) 52-57
10. Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101 (2000) 1729-1735
11. Querejeta R., Lopez B., Gonzalez A., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110 (2004) 1263-1268
12. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002) 2512-2517
13. Hayashi M., Tsutamoto T., Wada A., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents postinfarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107 (2003) 2559-2565
14. Izawa H., Murohara T., Nagata K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112 (2005) 2940-2945
15. Lopez B., Gonzalez A., Querejeta R., et al. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48 (2006) 89-96
16. Lalu M.M., Pasini E., Schulze C.J., et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26 (2005) 27-35
17. Inokubo Y., Hanada H., Ishizaka H., et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2001) 211-217
18. Carver W., Nagpal M.L., Nachtigal M., et al. Collagen expression in mechanically stimulated cardiac fibroblasts. Circ Res 69 (1991) 116-122
19. Mukherjee D., and Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res 67 (1990) 1474-1480
20. Nakahara T., Takata Y., Hirayama Y., et al. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J 71 (2007) 716-721
21. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113 (2006) 2089-2096
22. Martos R., Baugh J., Ledwidge M., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115 (2007) 888-895
23. Lindsay M.M., Maxwell P., and Dunn F.G. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40 (2002) 136-141
24. Muller-Brunotte R., Kahan T., Lopez B., et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 25 (2007) 1958-1966
25. Poulsen S.H., Andersen N.H., Heickendorff L., et al. Relation between plasma amino-terminal propeptide of procollagen type III and left ventricular longitudinal strain in essential hypertension. Heart 91 (2005) 624-629
26. Gonzalez-Vilchez F., Ayuela J., Ares M., et al. Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int J Cardiol 101 (2005) 53-58
27. Alla F., Kearney-Schwartz A., Radauceanu A., et al. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail 8 (2006) 147-153
28. Berg T.J., Snorgaard O., Faber J., et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22 (1999) 1186-1190
29. Quilliot D., Alla F., Bohme P., et al. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond) 29 (2005) 1321-1328
30. Diez J. Arterial stiffness and extracellular matrix. Adv Cardiol 44 (2007) 76-95
31. Ishikawa J., Kario K., Matsui Y., et al. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy. Hypertens Res 28 (2005) 995-1001
32. Kitahara T., Takeishi Y., Arimoto T., et al. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ J 71 (2007) 929-935
33. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 108 (2003) 1395-1403
34. Jugdutt B.I. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 3 (2003) 1-30
35. Radauceanu A., Moulin F., Djaballah W., et al. Residual stress ischaemia is associated with blood markers of myocardial structural remodeling. Eur J Heart Fail 9 (2007) 370-376
36. Uusimaa P., Risteli J., Niemela M., et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 96 (1997) 2565-2572
37. Poulsen S.H., Host N.B., Jensen S.E., et al. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 101 (2000) 1527-1532
38. Papadopoulos D.P., Moyssakis I., Makris T.K., et al. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction. Eur Cytokine Netw 16 (2005) 152-160
39. Iraqi W., Rossignol P., Fay R., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the EPHESUS study. Circ J 119 (2009) 2471-2479
40. Murakami T., Kusachi S., Murakami M., et al. Time-dependent changes of serum carboxy-terminal peptide of type I procollagen and carboxy-terminal telopeptide of type I collagen concentrations in patients with acute myocardial infarction after successful reperfusion: correlation with left ventricular volume indices. Clin Chem 44 (1998) 2453-2461
41. Cerisano G., Pucci P.D., Sulla A., et al. Relation between plasma brain natriuretic peptide, serum indexes of collagen type I turnover, and left ventricular remodeling after reperfused acute myocardial infarction. Am J Cardiol 99 (2007) 651-656
42. Webb C.S., Bonnema D.D., Ahmed S.H., et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114 (2006) 1020-1027
43. Mukherjee D., and Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest 88 (1991) 1141-1146
44. Klappacher G., Franzen P., Haab D., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995) 913-918
45. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 102 (2000) 2700-2706
46. Radauceanu A., Ducki C., Virion J.M., et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 14 (2008) 467-474
47. Nishio Y., Sato Y., Taniguchi R., et al. Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ J 71 (2007) 631-635
48. Rossi A., Cicoira M., Bonapace S., et al. Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction. Heart 93 (2007) 1420-1425
49. Bonapace S., Rossi A., Cicoira M., et al. Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy. Am Heart J 152 93 (2006) e1-e6
50. Everett IV T.H., and Olgin J.E. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4 (2007) S24-S27
51. Polyakova V., Miyagawa S., Szalay Z., et al. Atrial extracellular matrix remodeling in patients with atrial fibrillation. J Cell Mol Med 12 (2008) 189-208
52. Kallergis E.M., Manios E.G., Kanoupakis E.M., et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 52 (2008) 211-215
53. Shimano M., Shibata R., Tsuji Y., et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 72 (2008) 1120-1124
54. Tziakas D.N., Chalikias G.K., Papanas N., et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace 9 (2007) 589-596
55. Tziakas D.N., Chalikias G.K., Stakos D.A., et al. Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. Expert Opin Pharmacother 8 (2007) 2225-2234
56. Blangy H., Sadoul N., Dousset B., et al. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 9 (2007) 724-729
57. Ciulla M.M., Paliotti R., Esposito A., et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 110 (2004) 552-557
58. Funder J.W. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 147 (2006) 5564-5567
59. Young M.J. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 17 (2008) 174-180
60. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
61. Sato A., Takane H., and Saruta T. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res 24 (2001) 99-104
62. Zannad F., and Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev 10 (2005) 71-78
63. Majima T., Komatsu Y., Fukao A., et al. Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocrinol Jpn 54 (2007) 145-151
64. Rajagopalan S., Zannad F., Radauceanu A., et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 100 (2007) 222-226
65. Zucker S., Hymowitz M., Conner C., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 878 (1999) 212-227
66. Garnero P., Bianchi F., Carlier M.C., et al. [Biochemical markers of bone remodeling: pre-analytical variations and guidelines for their use. SFBC (Societe Francaise de Biologie Clinique) Work Group. Biochemical markers of bone remodeling]. Ann Biol Clin (Paris) 58 (2000) 683-704
67. Fontaine V., Jacob M.P., Houard X., et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 161 (2002) 1701-1710
68. Jung K., Nowak L., Lein M., et al. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem 42 (1996) 2043-2045
69. Zucker S., Doshi K., and Cao J. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications. Adv Clin Chem 38 (2004) 37-85
70. Cremers S., and Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66 (2006) 2031-2058